Fabry disease is a rare genetic condition in which the body cannot properly break down a specific type of fat molecule, causing it to build up inside cells throughout the body. Over time, this accumulation damages the kidneys, heart, brain, and nervous system. Global prevalence estimates range from 1 in 40,000 to 1 in 170,000, though in the United States the figure is closer to 1 in 22,000, suggesting many cases go undiagnosed.
What Happens Inside the Body
Fabry disease belongs to a group of conditions called lysosomal storage disorders. Every cell contains tiny compartments called lysosomes that act like recycling centers, breaking down waste materials so the cell can reuse or discard them. In Fabry disease, a mutation in the GLA gene means the body produces little or no functional version of a key enzyme responsible for breaking down a fatty substance called globotriaosylceramide (Gb3 for short).
Without enough of this enzyme, Gb3 and its byproducts steadily accumulate in lysosomes across a wide range of tissues: blood vessel walls, heart muscle cells, kidney cells, and neurons in both the central and peripheral nervous systems. This buildup is what drives every symptom of the disease, starting subtly in childhood and progressing toward serious organ damage in adulthood.
How Fabry Disease Is Inherited
The GLA gene sits on the X chromosome, making Fabry disease an X-linked condition. Males have only one X chromosome, so a single altered copy of the gene is enough to cause the disease. Females have two X chromosomes, which often provides partial protection because the healthy copy can still produce some enzyme. As a result, symptoms in women typically appear later in life and tend to be milder than in male relatives with the same mutation.
That said, Fabry disease is unusual among X-linked disorders because it causes significant medical problems in many female carriers. Women can develop chronic pain, kidney disease, heart problems, stroke, and fatigue. Only a small percentage of women who carry the mutation never develop any symptoms at all.
Classic vs. Late-Onset Types
Fabry disease falls into two broad categories depending on how much residual enzyme activity a person retains.
The classic form, most common in males with virtually no enzyme activity, produces symptoms starting in childhood. These patients develop the full spectrum of complications and experience their first major medical event (such as kidney failure, stroke, or severe heart disease) at a median age of around 50. Men with classic Fabry disease are first evaluated by specialists at an average age of 38, and women with the classic form at about 41.
The late-onset (or nonclassical) form involves some residual enzyme activity, which delays and limits the damage. Symptoms may be confined to a single organ, often the heart. Many of these patients are only discovered through screening programs for people who already have unexplained stroke, kidney failure, or thickening of the heart muscle. Men with the late-onset form aren’t typically seen by a specialist until their mid-50s. The risk of serious complications is substantially lower: men with classic disease face roughly five to six times the rate of major events compared to those with nonclassical disease.
Early Symptoms in Children and Young Adults
The earliest signs of Fabry disease are easy to overlook or attribute to other causes, which is one reason diagnosis is often delayed by years.
- Burning pain in hands and feet. Called acroparesthesia, this chronic tingling or burning sensation results from damage to small nerve fibers. It is common in boys and reported in a wide range of girls with the condition. Pain crises can be triggered by heat, exercise, or fever.
- Reduced sweating. Difficulty sweating (hypohidrosis) is one of the most common childhood signs. In one European study, 93% of boys and 25% of girls with Fabry disease had reduced sweating. The median age of onset was 13 in boys and 29 in women.
- Heat intolerance. Because sweat glands don’t function properly, affected children often struggle in warm weather or during physical activity. About half of both boys and girls report heat intolerance.
- Stomach problems. Cramping, nausea, diarrhea, and abdominal pain after eating are frequently among the first complaints.
- Skin lesions. Small, dark red raised spots called angiokeratomas may appear as clusters of deep red dots, typically in the area between the navel and the knees (the “bathing trunk” region). In older males these can number over 100 and range from 1 to 10 millimeters, appearing as red to black papules.
Because these symptoms are nonspecific, children are often misdiagnosed with growing pains, rheumatic conditions, or irritable bowel syndrome before anyone considers Fabry disease.
Major Organ Complications
As Gb3 continues to accumulate over decades, the disease progressively damages three organ systems that determine long-term outcomes.
Heart
The heart is the most vulnerable organ in Fabry disease and the most common source of serious complications. The fatty deposits cause the walls of the heart to thicken (left ventricular hypertrophy), disrupt the electrical conduction system, and can lead to dangerous arrhythmias and valve disease. Cardiac complications are the leading cause of death in both men and women with Fabry disease.
Kidneys
Gb3 accumulates in the filtering cells of the kidneys, gradually destroying their ability to retain protein and clear waste from the blood. This progresses from protein in the urine to chronic kidney disease and, in classic cases, kidney failure requiring dialysis or transplant.
Brain and Blood Vessels
Damage to blood vessel walls increases the risk of transient ischemic attacks (mini-strokes) and full strokes, sometimes occurring in relatively young adults. These vascular events are a major source of disability and early death.
How Fabry Disease Is Diagnosed
The path to diagnosis differs significantly between men and women. In males, a blood test measuring the activity of the deficient enzyme is reliable. Men with Fabry disease consistently show low or absent enzyme levels, making this a straightforward first step.
For women, the enzyme test misses the majority of cases. More than 70% of female patients have enzyme levels that fall within the normal range, regardless of whether they have the classic or late-onset form. This means genetic testing, which directly looks for mutations in the GLA gene, is the only reliable way to confirm or rule out Fabry disease in women. Genetic testing is also essential for identifying the specific mutation, which matters for treatment decisions.
Treatment Options
There is no cure for Fabry disease, but treatments can slow its progression and manage symptoms.
The primary approach is enzyme replacement therapy, which involves intravenous infusions of a manufactured version of the missing enzyme every two weeks for life. Two versions are available globally. These infusions help clear the accumulated fatty deposits from cells and can slow kidney decline, reduce heart thickening, and improve pain. However, the infused enzyme cannot cross into the brain, so it does not address neurological damage directly.
An oral alternative works differently. Rather than replacing the enzyme, this pill-form medication acts as a molecular chaperone, stabilizing the patient’s own faulty enzyme so it can still function partially. It was approved in the U.S. in 2018 for adults whose specific genetic mutation responds to the drug. Not all mutations are eligible: lab testing has identified roughly 1,400 mutations that respond and about 750 that do not. Your specific mutation must be checked against an amenability database before this treatment can be prescribed, and kidney function must be above a certain threshold.
Beyond these disease-specific therapies, managing Fabry disease involves treating organ damage as it arises: medications for pain, blood pressure control to protect the kidneys, cardiac monitoring, and stroke prevention strategies. Starting treatment early, before irreversible organ damage occurs, produces the best outcomes, which is why early diagnosis matters so much in this condition.